In a report released yesterday, Yaron Werber from Cowen & Co. maintained a Buy rating on Dicerna Pharma (DRNA). The company’s shares closed last Monday at $21.39, close to its 52-week high of $23.57.
According to TipRanks.com, Werber is a 5-star analyst with an average return of 10.4% and a 59.3% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Springworks Therapeutics, and Rocket Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dicerna Pharma with a $25.67 average price target, representing a 21.9% upside. In a report issued on November 8, H.C. Wainwright also maintained a Buy rating on the stock with a $22.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $23.57 and a one-year low of $9.31. Currently, Dicerna Pharma has an average volume of 543.5K.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DRNA in relation to earlier this year. Last month, James Weissman, the EVP & COO of DRNA bought 4,904 shares for a total of $16,772.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas.
